bradanicline   Click here for help

GtoPdb Ligand ID: 3969

Synonyms: ATA-101 | ATA101 | compound 7a [PMID 23126648] [4] | TC-5619 | TC5619
Compound class: Synthetic organic
Comment: Bradanicline is an investigational agonist of neuronal α7 subunit-containing nicotinic acetylcholine receptors [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 58.37
Molecular weight 361.18
XLogP 2.55
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(c1cc2c(o1)cccc2)NC1C2CCN(C1Cc1cccnc1)CC2
Isomeric SMILES O=C(c1cc2c(o1)cccc2)N[C@@H]1C2CCN([C@H]1Cc1cccnc1)CC2
InChI InChI=1S/C22H23N3O2/c26-22(20-13-17-5-1-2-6-19(17)27-20)24-21-16-7-10-25(11-8-16)18(21)12-15-4-3-9-23-14-15/h1-6,9,13-14,16,18,21H,7-8,10-12H2,(H,24,26)/t18-,21+/m0/s1
No information available.
Summary of Clinical Use Click here for help
Bradanicline has completed Phase 2 clinical trials as a potential treatment for the cognitive impairment associated with schizophrenia [3] and attention deficit/hyperactivity disorder (ADHD). Attenua are repurposing bradanicline as a novel intervention for refractory chronic cough [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03622216 A Dose Escalation Study of Bradanicline in Refractory Chronic Cough Phase 2 Interventional Attenua, Inc.